Creo Medical Group PLC Net Assets

Latest as of December 2025: GBX50.00 Million GBX ≈ $6.08K USD

Creo Medical Group PLC net assets. Based on the latest financial reports, Creo Medical Group PLC (CREO) has net assets worth GBX50.00 Million GBX (≈ $6.08K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX59.10 Million ≈ $7.19K USD) and total liabilities (GBX9.10 Million ≈ $1.11K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CREO net assets growth trend to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX50.00 Million
% of Total Assets 84.6%
Annual Growth Rate N/A
5-Year Change -31.8%
10-Year Change 241.24%
Growth Volatility 381.98

Net Assets of Creo Medical Group PLC (2005–2025)

Net assets of Creo Medical Group PLC from 2005 to 2025. This chart illustrates how Creo Medical Group PLC's net assets have evolved over time, based on quarterly financial data. See Creo Medical Group PLC balance sheet quality to measure how much of total assets are equity-financed.

Annual Net Assets for Creo Medical Group PLC (2005–2025)

The table below shows the annual net assets of Creo Medical Group PLC from 2005 to 2025. For live market cap and overall valuation, see Creo Medical Group PLC (CREO) total market value.

Year Net Assets Change
2025-12-31 GBX50.00 Million
≈ $6.08K		 +17.92%
2024-12-31 GBX42.40 Million
≈ $5.16K		 -29.10%
2023-12-31 GBX59.80 Million
≈ $7.28K		 +21.05%
2022-12-31 GBX49.40 Million
≈ $6.01K		 -32.62%
2021-12-31 GBX73.32 Million
≈ $8.92K		 +16.74%
2020-12-31 GBX62.81 Million
≈ $7.64K		 -24.02%
2019-12-31 GBX82.66 Million
≈ $10.06K		 +73.25%
2018-12-31 GBX47.71 Million
≈ $5.81K		 +551.03%
2018-06-30 GBX7.33 Million
≈ $891.73		 -49.98%
2017-06-30 GBX14.65 Million
≈ $1.78K		 +799.39%
2016-06-30 GBX1.63 Million
≈ $198.22		 -49.44%
2016-02-29 GBX3.22 Million
≈ $392.03		 +330.52%
2015-02-28 GBX748.41K
≈ $91.06		 -45.56%
2014-02-28 GBX1.37 Million
≈ $167.26		 +1116.51%
2008-02-29 GBX113.00K
≈ $13.75		 +841.67%
2007-02-28 GBX12.00K
≈ $1.46		 +500.00%
2006-02-28 GBX-3.00K
≈ $-0.37		 +75.00%
2005-02-28 GBX-12.00K
≈ $-1.46		 --

Equity Component Analysis

This analysis shows how different components contribute to Creo Medical Group PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1281766.7% over the analyzed period, potentially due to dividend distributions or operating losses.

Creo Medical Group PLC Net Assets Breakdown (December 2025)

Creo Medical Group PLC net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Common Stock GBX400.00K 0.80%
Other Comprehensive Income GBX11.50 Million 23.00%
Other Components GBX191.90 Million 383.80%
Total Equity GBX50.00 Million 100.00%

Creo Medical Group PLC Competitors by Market Cap

The table below lists competitors of Creo Medical Group PLC ranked by their market capitalization.

Company Market Cap
Prostatype Genomics AB
ST:PROGEN
 $628.05K
Oriental Rise Holdings Limited Ordinary Shares
NASDAQ:ORIS
 $632.10K
Arcandor AG
DU:ARO
 $633.07K
Kovo Healthtech Corp
V:KOVO
 $639.80K
Newtopia Inc
V:NEWU
 $626.69K
ODINWELL AB
F:0AF
 $626.64K
Cora Gold Limited
LSE:CORA
 $626.39K
COPPERCORP RESOURCES INC.
F:NU0
 $625.83K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Creo Medical Group PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 42,400,000 to 50,000,000, a change of 7,600,000 (17.9%).
  • Net income of 5,300,000 contributed positively to equity growth.
  • Share repurchases of 100,000 reduced equity.
  • Other comprehensive income decreased equity by 11,599,999.
  • Other factors increased equity by 13,999,999.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX5.30 Million +10.6%
Share Repurchases GBX100.00K -0.2%
Other Comprehensive Income GBX-11.60 Million -23.2%
Other Changes GBX14.00 Million +28.0%
Total Change GBX- 17.92%

Book Value vs Market Value Analysis

This analysis compares Creo Medical Group PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 87.64x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 647.24x to 87.64x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-02-28 GBX0.02 GBX10.63 x
2015-02-28 GBX0.01 GBX10.63 x
2016-02-29 GBX0.04 GBX10.63 x
2017-06-30 GBX0.24 GBX10.63 x
2018-06-30 GBX0.09 GBX10.63 x
2018-12-31 GBX0.51 GBX10.63 x
2019-12-31 GBX0.66 GBX10.63 x
2020-12-31 GBX0.39 GBX10.63 x
2021-12-31 GBX0.43 GBX10.63 x
2022-12-31 GBX0.26 GBX10.63 x
2023-12-31 GBX0.19 GBX10.63 x
2024-12-31 GBX0.12 GBX10.63 x
2025-12-31 GBX0.12 GBX10.63 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Creo Medical Group PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.60%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 88.33%
  • • Asset Turnover: 0.10x
  • • Equity Multiplier: 1.18x
  • Recent ROE (10.60%) is above the historical average (-76.11%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -123.43% -211.43% 0.49x 1.18x GBX-1.83 Million
2015 -318.28% 0.00% 0.00x 1.40x GBX-2.46 Million
2016 -103.34% -622.74% 0.14x 1.17x GBX-3.65 Million
2016 -99.02% -317.43% 0.21x 1.48x GBX-1.78 Million
2017 -53.00% 0.00% 0.00x 1.10x GBX-9.23 Million
2018 -114.73% 0.00% 0.00x 1.31x GBX-9.14 Million
2018 -20.69% 0.00% 0.00x 1.04x GBX-14.64 Million
2019 -19.25% -118096.56% 0.00x 1.07x GBX-24.18 Million
2020 -32.35% -215.46% 0.10x 1.47x GBX-26.60 Million
2021 -33.55% -97.75% 0.25x 1.37x GBX-31.93 Million
2022 -54.52% -99.14% 0.36x 1.52x GBX-31.88 Million
2023 -36.29% -70.45% 0.40x 1.28x GBX-27.68 Million
2024 -67.69% -717.50% 0.06x 1.53x GBX-32.94 Million
2025 10.60% 88.33% 0.10x 1.18x GBX300.00K

Industry Comparison

This section compares Creo Medical Group PLC's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $56,098,559
  • Average return on equity (ROE) among peers: -18.33%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Creo Medical Group PLC (CREO) GBX50.00 Million -123.43% 0.18x $628.03K
AOTI Inc (AOTI) $-5.91 Million 0.00% 0.00x $1.74 Million
EKF Diagnostics Holdings Plc (EKF) $68.22 Million 3.45% 0.19x $1.27 Million
Inspiration Healthcare Group PLC (IHC) $28.97 Million -20.83% 0.69x $190.92K
NIOX Group PLC (NIOX) $66.80 Million 5.39% 0.29x $3.28 Million
Polarean Imaging Plc (POLX) $7.79 Million -72.42% 0.26x $11.75K
Rua Life Sciences PLC (RUA) $5.41 Million -35.53% 0.12x $192.55K
Smith & Nephew PLC (SN) $273.58 Million 25.01% 1.35x $118.24 Million
Surgical Innovations Group plc (SUN) $3.93 Million -51.73% 0.98x $36.89K

About Creo Medical Group PLC

LSE:CREO UK Medical Devices
Market Cap
$628.03K
GBX5.16 Billion GBX
Market Cap Rank
#30937 Global
#878 in UK
Share Price
GBX10.63
Change (1 day)
-2.30%
52-Week Range
GBX9.65 - GBX17.75
All Time High
GBX243.00
Categories
Companies in UK Medical Devices
About

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices del… Read more